» Authors » Ann J Hessell

Ann J Hessell

Explore the profile of Ann J Hessell including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 3935
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shapiro M, Ordonez T, Pandey S, Mahyari E, Onwuzu K, Reed J, et al.
JCI Insight . 2024 Aug; 9(19). PMID: 39190496
Transmission of HIV-1 to newborns and infants remains high, with 130,000 new infections in 2022 in resource-limited settings. Half of HIV-infected newborns, if untreated, progress to disease and death within...
2.
Heindel D, Figueroa Acosta D, Goff M, Yengo C, Jan M, Liu X, et al.
iScience . 2024 Aug; 27(8):110390. PMID: 39108723
Bacteria dysbiosis and its accompanying inflammation or compromised mucosal integrity is associated with an increased risk of HIV-1 transmission. However, HIV-1 may also bind bacteria or bacterial products to impact...
3.
Kelkar N, Goldberg B, Dufloo J, Bruel T, Schwartz O, Hessell A, et al.
mBio . 2024 Feb; 15(3):e0028224. PMID: 38385704
The complement system can be viewed as a "moderator" of innate immunity, "instructor" of humoral immunity, and "regulator" of adaptive immunity. While sex is known to affect humoral and cellular...
4.
Hioe C, Liu X, Banin A, Heindel D, Klingler J, Rao P, et al.
Front Immunol . 2023 Nov; 14:1329069. PMID: 38022586
[This corrects the article DOI: 10.3389/fimmu.2023.1271686.].
5.
Kelkar N, Goldberg B, Dufloo J, Bruel T, Schwartz O, Hessell A, et al.
bioRxiv . 2023 Nov; PMID: 37961263
The complement system can be viewed as a 'moderator' of innate immunity, 'instructor' of humoral immunity, and 'regulator' of adaptive immunity. While sex and aging are known to affect humoral...
6.
Streblow D, Hirsch A, Stanton J, Lewis A, Colgin L, Hessell A, et al.
Nat Commun . 2023 Nov; 14(1):7062. PMID: 37923717
Passively administered monoclonal antibodies (mAbs) given before or after viral infection can prevent or blunt disease. Here, we examine the efficacy of aerosol mAb delivery to prevent infection and disease...
7.
Prevost J, Chen Y, Zhou F, Tolbert W, Gasser R, Medjahed H, et al.
Nat Commun . 2023 Oct; 14(1):6710. PMID: 37872202
The HIV-1 entry inhibitor temsavir prevents the viral receptor CD4 (cluster of differentiation 4) from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this, temsavir...
8.
Hioe C, Liu X, Banin A, Heindel D, Klingler J, Rao P, et al.
Front Immunol . 2023 Oct; 14:1271686. PMID: 37854587
Introduction: Neutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable of eliciting neutralizing Abs effective against a broad array of...
9.
Goldberg B, Spencer D, Pandey S, Ordonez T, Barnette P, Yu Y, et al.
Proc Natl Acad Sci U S A . 2023 May; 120(20):e2221247120. PMID: 37155897
The first clinical efficacy trials of a broadly neutralizing antibody (bNAb) resulted in less benefit than expected and suggested that improvements are needed to prevent HIV infection. While considerable effort...
10.
Prevost J, Chen Y, Zhou F, Tolbert W, Gasser R, Medjahed H, et al.
bioRxiv . 2023 May; PMID: 37131729
The HIV-1 entry inhibitor temsavir prevents CD4 from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this temsavir relies on the presence of a residue...